Equities analysts predict that VYNE Therapeutics Inc. (NASDAQ:VYNE) will announce earnings per share of ($0.34) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for VYNE Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.36). VYNE Therapeutics posted earnings per share of ($0.52) in the same quarter last year, which indicates a positive year-over-year growth rate of 34.6%. The business is expected to announce its next earnings results on Thursday, November 4th.
According to Zacks, analysts expect that VYNE Therapeutics will report full year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.35) to ($1.25). For the next financial year, analysts anticipate that the company will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.85) to ($0.58). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for VYNE Therapeutics.
VYNE Therapeutics (NASDAQ:VYNE) last issued its earnings results on Thursday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01. VYNE Therapeutics had a negative return on equity of 138.73% and a negative net margin of 554.66%. The firm had revenue of $4.26 million for the quarter, compared to the consensus estimate of $6.19 million.
Shares of NASDAQ VYNE opened at $1.48 on Friday. The business’s 50-day moving average price is $2.24 and its two-hundred day moving average price is $4.06. VYNE Therapeutics has a one year low of $1.37 and a one year high of $13.20. The company has a market capitalization of $76.24 million, a P/E ratio of -0.76 and a beta of 0.68.
In related news, major shareholder Perceptive Advisors Llc sold 250,000 shares of the business’s stock in a transaction dated Monday, August 16th. The stock was sold at an average price of $1.74, for a total transaction of $435,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 2.80% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of VYNE. Franklin Resources Inc. raised its holdings in VYNE Therapeutics by 12.5% in the 2nd quarter. Franklin Resources Inc. now owns 1,900,863 shares of the company’s stock valued at $6,672,000 after acquiring an additional 211,600 shares in the last quarter. 683 Capital Management LLC acquired a new position in VYNE Therapeutics in the 2nd quarter valued at approximately $2,575,000. Millennium Management LLC raised its holdings in VYNE Therapeutics by 2,513.0% in the 2nd quarter. Millennium Management LLC now owns 679,211 shares of the company’s stock valued at $2,384,000 after acquiring an additional 653,217 shares in the last quarter. Renaissance Technologies LLC acquired a new position in VYNE Therapeutics in the 2nd quarter valued at approximately $1,091,000. Finally, Morgan Stanley raised its holdings in VYNE Therapeutics by 438.6% in the 2nd quarter. Morgan Stanley now owns 203,075 shares of the company’s stock valued at $713,000 after acquiring an additional 165,372 shares in the last quarter. 35.45% of the stock is owned by institutional investors and hedge funds.
About VYNE Therapeutics
VYNE Therapeutics, Inc engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company is headquartered in Bridgewater, NJ.
See Also: What is a short straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.